Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) shares gapped down prior to trading on Wednesday following a weaker than expected earnings announcement. The stock had previously closed at $1.58, but opened at $1.74. Aralez Pharmaceuticals shares last traded at $1.73, with a volume of 342908 shares changing hands.
The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The company had revenue of $28.02 million for the quarter, compared to analysts’ expectations of $25.75 million. Aralez Pharmaceuticals had a negative return on equity of 118.13% and a negative net margin of 112.89%.
Separately, HC Wainwright started coverage on shares of Aralez Pharmaceuticals in a research report on Monday, February 5th. They set a “buy” rating and a $6.00 price target on the stock.
The stock has a market capitalization of $135.11, a PE ratio of -1.02 and a beta of 1.41. The company has a quick ratio of 0.92, a current ratio of 1.00 and a debt-to-equity ratio of 4.64.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.